RXRX Tests $5 Support Amid Biotech De-Risking
$Recursion Pharmaceuticals, Inc.(RXRX)$
$5.00 (−8.09%): Pre-earnings flush pushes price back to $5 floor, now 60% below 52-week high $12.36
Market Recap (as of Nov 4 2025):
Recursion Pharmaceuticals closed at $5.00, down 8.09% on the day, with volume (~41.6M) slightly above its recent average (~39.1M), indicating active selling into weakness.
The stock is roughly 60% below its 52-week high of $12.36, reflecting heavy derating after earlier AI-drug-discovery hype.
Earnings are due Nov 5, so today’s move likely reflects de-risking ahead of the print plus cautious sentiment in high-beta biotech.
Technical Indicators Analysis:
On the daily chart, RXRX slipped back under both the 20-day EMA (~$5.68) and 50-day EMA (~$5.50), confirming a short-term downtrend.
MACD has rolled over toward the zero line with a fresh bearish crossover, while RSI sits near 42 — weak but not yet oversold, leaving room for further volatility.
Parabolic-SAR-style trend systems would still flag a sell bias as price trades below falling EMAs with expanding red candles. Immediate support sits near $4.45 -4.80, and the prior base around $3.80; resistance is $5.81, then $7.15
Valuation and Target Range:
With negative earnings, RXRX’s TTM P/E is around −2.8, versus the S&P 500’s ~28–31x trailing and ~23x forward P/E — the market is clearly pricing RXRX on pipeline option value rather than current profitability.
Analyst 12-month target averages cluster around $6.5–7.3 (high up to $10, low $3–5), implying ~30–45% upside from the current $5 level if execution improves.
For the next 1–2 weeks, base case is choppy trading between $4.80–5.70; a decisive close above $6.00 would open $6.80–7.20, while a breakdown below $4.80 risks a retest of $4.00–3.80.
Risk Statement:
RXRX is a small-cap, loss-making biotech with binary event risk around clinical and partnership news; price can move sharply in both directions, especially around earnings and data releases. This note is for technical reference only, does not constitute investment advice, and does not consider your individual financial situation or risk tolerance.
For SG users only, a tool to boost your purchasing power and trading ideas with a Cash Boost Account!
Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
